



Peter R. Mertens

Klinik für Nieren- u. Hochdruckkrankheiten
Diabetologie und Endokrinologie
Otto-von-Guericke-Universität Magdeburg
Leipziger Str. 44
39120 Magdeburg
E-Mail: peter.mertens@med.ovg.de

Persönliche Angaben

geboren: 02.04.1964 in Linnich

Ausbildung

1983: Abitur, Couven Gymnasium in Aachen

1983: Wintersemester: Chemiestudium an der RWTH Aachen

1984: ab Sommersemester Studium der Humanmedizin an der Heinrich-Heine Universität Düsseldorf

1989: Auslandsaufenthalt und Famulaturen in Nyeri/Kenia, DAAD

1991: Drittes Staatsexamen

Ärztliche und wissenschaftliche Tätigkeit

1991-1992: Ziviler Ersatzdienst und Arzt im Praktikum an der Heinrich-Heine Universität Düsseldorf in der Medizinischen Klinik, Abteilung für Hämatologie, Onkologie und Immunologie
Leiter: Prof. Dr. W. Schneider

1992: Approbation als Arzt

1992: Promotion mit der Arbeit: „Die hormonelle Regulation der Adenylatzyklase einer medullären Schilddrüsenkarzinom-Zelllinie“, Betreuer: Prof. Dr. Dr. E. Keck
Bewertung: „*summa cum laude*“

1992-1994: Wissenschaftlicher Assistent in der Medizinischen Klinik II, Abteilung für Nephrologie an der RWTH-Aachen,
Leiter: Prof. Dr. H.-G. Sieberth

1993: USMLE, step 1 (*US medical licensing examination*)

1994: USMLE, step 2 (*US medical licensing examination*)

- 1995-1996:** Verleihung eines Ausbildungsstipendiums der DFG (Me 1365) am SFVAMC/*University of California in San Francisco*, USA bei Prof. Dr. D.H. Lovett. Arbeit über Pathomechanismen bei der Entstehung und Progression glomerulärer Erkrankungen
- 01/1997-06/1997:** *Research Fellow* SFVAMC/*University of California in San Francisco*, USA. Arbeitsgruppe: Prof. Dr. D.H. Lovett
- 07/1997-06/1998:** Facharztweiterbildung an den Medizinischen Kliniken der RWTH-Aachen, wissenschaftlicher Assistent in der Medizinischen Klinik II, Abteilung für Nephrologie, Hämatologie und Immunologie, Leiter: Prof. Dr. H.-G. Sieberth
- 06/1998:** Erlangung der Gebietsbezeichnung für Innere Medizin
- 05/1999-03/2009:** Oberarzt der Medizinischen Klinik II
- 06/1999:** Wissenschaftlicher Oberassistent (C1)
- 11/1999:** *Venia legendi* für das Fach Innere Medizin
- 12/2000-03/2009:** Wissenschaftlicher Oberassistent (C2)
- 07/2001-03/2009:** Projektbereichsleiter im Sonderforschungsbereich 542 „Molekulare Mechanismen Zytokin-gesteuerter Entzündungsprozesse: Signaltransduktion und pathophysiologische Konsequenzen“
- 03/2003:** Erlangung der Teilgebietsbezeichnung für „Nephrologie“
- 05/2005:** Ernennung zum außerplanmäßigen Professor
- 10/2006:** Mitgründer der *antikoerper-online* GmbH, wissenschaftlich beratende Funktion
- 12/2006:** Erlangung der Zusatzbezeichnung „Diabetologie“
- 04/2007 – 04/2009:** Mitglied des „*Young Nephrology Committee*“ der International Society of Nephrology
- 05/2007:** Antragsteller DFG-Projekt: Einfluss des *Y-box* Proteins-1 auf die Notch-Signaltransduktion und Zelldifferenzierung (ME 1365/6-1)
- 09/2007:** Erlangung der Zusatzbezeichnung Hypertensiologie (DHL)
- seit 04/2009:** Universitätsprofessur für Nephrologie (W3)
Direktor der Klinik für Nieren- und Hochdruckkrankheiten & Diabetologie und Endokrinologie
Otto-von-Guericke-Universität Magdeburg
- seit 2010:** Vorsitzender der Fach- und Prüfungskommission „Nephrologie“ und Mitglied der Fach- und Prüfungskommission „Innere Medizin“ der Ärztekammer Sachsen-Anhalt

- seit 01/2010:** Stellvertretender Sprecher und Vorstandsmitglied des SFB854 „Molekulare Organisation der zellulären Kommunikation im Immunsystem“ (Förderung 01/2010 – 12/2017)
- seit 10/2012:** Prodekan für Struktur der Medizinischen Fakultät der Otto-von-Guericke Universität Magdeburg
- seit 2013:** Mitglied der Walter-Siegenthaler Gesellschaft für Fortschritte in der Inneren Medizin
- 2015:** Mitgründer der [„mediXmind“ GmbH](#)
Fokus: Innovative Medizintechnik, vor allem für Diabetiker
- 2015 – 2019:** Mitglied des IMPP (Institute for medical and pharmaceutical examinations, Mainz)

Klinische Schwerpunkte

Nephrologie, Hypertensiologie, Diabetologie, Transplantation, Rheumatologie, Immunologie

Herausgeberschaft

Rationelle Diagnostik und Therapie in der Inneren Medizin (Nephrologie und Hochdruckkrankheiten) (seit 2009)

Mitgliedschaft im “Editorial Board” wissenschaftlicher Zeitschriften

- Clinical Nephrology (seit 06/2005)
- Nephrology Dialysis Transplantation (seit 05/2007)
- Journal of Molecular Medicine (seit 04/2010)
- International Urology and Nephrology (Section Editor Translational Nephrology seit 01/2010)

Mitgliedschaften bei wissenschaftlichen Gesellschaften

- American Society of Nephrology (ASN)
- Deutsche Gesellschaft für Nephrologie (GfN)
- Deutsche Gesellschaft für Innere Medizin (DGIM)
- European Renal Assoc.-European Dialysis & Transplantation Association (ERA-EDTA)
- International Society of Nephrology (ISN)

Preise und Auszeichnungen

- 2006 Fritz-Linder-Forumspreis Deutsche Gesellschaft für Chirurgie
Lynen Jansen P., Klinge U., Hungol M., Krott E., Lovett D.H., Jansen M., Mertens P.R.
- 2006 Franz Volhard Preis (höchste Auszeichnung der Deutschen Gesellschaft für Nephrologie)

Magdeburg, den 15.05.2015

BIBLIOGRAPHIE

ORIGINALARBEITEN

- [1] **Mertens P.R.**, Duque-Reina D., Ittel T.H., Keulers P., Sieberth H.G. (1994) Contrast-enhanced computed tomography for demonstration of bilateral renal cortical necrosis. *Clin. Investig.* 72: 499-501 IF: 1,865
- [2] Harendza S., Pollock A.S., **Mertens P.R.**, and Lovett D.H. (1995) Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. *J. Biol. Chem.* 270: 18786-18796 IF: 4,651
- [3] Busch N., **Mertens P.R.**, Schonfelder T., Nguyen H., Marschall H.U., Kierdorf H., Haase G., Urhahn R., Sieberth H.G., Matern S. (1996) Lemierre's post-tonsillitis sepsis with meningitis and intravascular consumption coagulopathy as complication of infectious mononucleosis with pansinusitis. *Dtsch. Med. Wochenschr.* 121: 94-98 IF: 0,584
- [4] **Mertens P.R.**, Harendza S., Pollock A.S., and Lovett D.H. (1997) Glomerular mesangial cell-specific transactivation of MMP-2 transcription is mediated by YB-1. *J. Biol. Chem.* 272: 22905-22912 IF: 4,651
- [5] **Mertens P.R.**, Jaume A., Steinmann K., and Lovett D.H. (1998) A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. *J. Biol. Chem.* 273: 32957-32965 IF: 4,651
- [6] **Mertens P.R.**, Espenkott V., Venjakob B., Handt S., Heintz B., and Sieberth H.-G. (1998) Pressure oscillation regulates human mesangial cell growth and collagen synthesis. *Hypertension* 32: 945-952 IF: 6,873
- [7] **Mertens P.R.**, Goretzki P., and Keck E. (1999) cAMP synthesis in a medullary thyroid carcinoma cell line: response to adrenergic agents and prostaglandines. *Exp. Clin. Endocrinol. Diabetes* 107: 488-495 IF: 1,555
- [8] **Mertens P.R.**, Alfonso-Jaume M.A., Steinmann K., Lovett D.H. (1999) YB-1 regulation of the human and rat gelatinase A genes via similar enhancer elements. *J. Am. Soc. Nephrol.* 10: 2480-2487 IF: 8,987
- [9] Makropoulos W., Kocher K., Heintz B., Schwarz E.R., **Mertens P.R.**, Stefanidis I. (2000) Urinary thymidine glycol as a biomarker for oxidative stress after kidney transplantation. *Ren. Fail.* 22: 499-510 IF: 0,941
- [10] Norman J.T., Lindahl G.E., Shakib K., En-Nia A., Yilmaz E., **Mertens P.R.** (2001) The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter. *J. Biol. Chem.* 276: 29880-29890 IF: 4,651
- [11] Stefanidis I., **Mertens P.R.**, Wurth P., Bach R., Makropoulos W., Mann H., Heintz B. (2001) Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis. *Int. J. Artif. Organs.* 24: 367-373 IF: 1,759

- [12] En-Nia A., Reisdorff J., Stefanidis I., Floege J., Heinrich P.C., **Mertens P.R.** (2002) Mesangial cell gelatinase A synthesis is attenuated by oscillating hyperbaric pressure. *Biochem. J.*, 362: 693-700 IF: 4,654
- [13] Si Z.Y., Bhardwai R.S., Rosch R., **Mertens P.R.**, Klinge U., Klosterhalfen B. (2002) Impaired balance of type I and type III procollagen mRNA in cultured fibroblasts of patients with incisional hernia. *Surgery*, 131: 324-331 IF: 3,373
- [14] Hahn A., Barth H., Kress M., **Mertens P.R.**, Goppelt-Struebe M. (2002) Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expression. *Biochem. J.*, 362: 33-40 IF: 4,654
- [15] Reisdorff J., En-Nia A., Stefanidis I., Floege J., Lovett D.H., **Mertens P.R.** (2002) Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. *J. Am. Soc. Nephrol.* 13: 1568-1578 IF: 8,987
- [16] Cheng S., Alfonso-Jaume M.A., **Mertens P.R.**, Lovett D.H. (2002) Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). *Biochem. J.* 366: 807-816 IF: 4,654
- [17] **Mertens P.R.**, Steinmann K., Alfonso-Jaume M.A., En-Nia A., Sun Y., Lovett D.H. (2002) Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. *J. Biol. Chem.* 277: 24875-24882 IF: 4,651
- [18] Raffetseder U, Frye B, Rauen T, Jürchott K, Royer H.D., **Mertens P.R.** (2003) Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. *J. Biol. Chem.*, 278: 18241-18248 IF: 4,651
- [19] Geier A., **Mertens P.R.**, Gerloff T., Dietrich C.G., En-Nia A., Kullak-Ublick G.A., Karpen S.J., Matern S., Gartung C. (2003) Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Y-box protein 1. *Biochem Biophys Res Commun.* 309: 612-618 IF: 2,406
- [20] Politt D., Heintz B., Floege J., **Mertens PR.** (2003) Tacrolimus (FK 506)-based immunosuppression in severe systemic lupus erythematosus. *Clin. Nephrol.* 62: 49-53 IF: 1,288
- [21] Steinmetz M.O., Panzer U., Harendza S., Schoder V., **Mertens P.R.**, Ostendorf T., Floege J., Helmchen U., Stahl R.A.K. (2003) No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. *Nephrology Dialysis Transplantation* 19: 596-601 IF: 3,371
- [22] Raffetseder U., Wernert N., Ostendorf T., van Roeyen C., Rauen T., Behrens P., Floege J., **Mertens P.R.** (2004) Mesangial cell expression of proto-oncogene Ets-1 during progression of mesangioproliferative glomerulonephritis. *Kidney Int.* 66: 622-632 IF: 7,916
- [23] Lynen Jansen P., Klinge U., Anurov M., Titkova S., **Mertens P.R.**, Jansen M. (2004) Surgical mesh as a scaffold for tissue regeneration in the esophagus. *Eur. Surg. Res.* 36: 104-111 IF: 0,750
- [24] Liakopoulos V., Petinaki E., Bouchlariotou S., **Mertens P.R.**, Trakala M., Kourti P., Riehl J., Ikononov V., Stefanidis I. (2004) Group B Streptococcus (Streptococcus

- agalactiae) peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).
Clin. Nephrol. 62: 391-396 IF: 1,288
- [25] Junge K., Rosch R., Klinge U., Krones C., Klosterhalfen B., **Mertens P.R.**, Lynen P., Kunz D., Preiss A., Peltroche-Llacsahuanga H., Schumpelick V. (2005) Gentamicin supplementation of polyvinylidene fluoride mesh materials for infection prophylaxis. *Biomaterials* 26: 787-793 IF: 7,604
- [26] En-Nia A., Yilmaz E., Lovett D.H., Stefanidis I., **Mertens P.R.** (2005) Serum-induced expression of the DNA-polymerase α gene is mediated by transcription factor YB-1. *J. Biol. Chem.* 280: 7702-77012 IF: 4,651
- [27] Weng H., Wang B.-N., Jia J.-D., Wu W.-F., Xian J.-Z., **Mertens P.R.**, Cai W.M., Dooley S. (2005) Effect of interferon gamma on hepatic fibrosis in chronic hepatitis B virus infection: A randomized controlled study. *Clinical Gastroenterology and Hepatology* 3: 819-828 IF: 6,648
- [28] Liakopoulos V., Wurth P., **Mertens P.R.**, Eleftheriadis T., Kourti P., Voliotis G., Heintz B., Stefanidis, I. (2005) Endothelin-1 plasma levels in hemodialysis treatment - the influence of type 2 diabetes. *Renal Failure* 27: 515-522 IF: 0,941
- [29] Stefanidis I., Bach R., **Mertens P.R.**, Liakopoulos V., Liapi G., Mann H., Heintz B. (2005) Influence of hemodialysis on the mean blood flow velocity in the middle cerebral artery. *Clin. Nephrol.* 64: 129-137 IF: 1,288
- [30] Filippidis G., Liakopoulos V., **Mertens P.R.**, Kiropoulos T., Stakias N., Verikouki C., Patsidis E., Koukoulis G., Stefanidis I. (2005) Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. *Blood Purif.* 23: 421-428 IF: 2,062
- [31] Schena F.P., Cerullo G., Torres D.D., Scolari F., Foramitti M., Amoroso A., Pirulli D., Floege J., **Mertens P.R.**, Zerres K., Alexopoulos E., Kirmizis D, Zelante L, Bisceglia L., Bisceglia L., Ghiggeri G.M., Frasca G.M., European IgA nephropathy consortium. (2005) The IgA nephropathy biobank. An important starting point for the genetic dissection of a complex trait. *BMC Nephrol.* 6: 14-22 IF: 1,644
- [32] van Roeyen C.R.C., Eitner F., Ostendorf T., Martinkus S., Royer H.D., Jurchat K., Floege J., **Mertens P.R.** (2005) Expression of YB-1, a central regulator of profibrotic factors, in glomerular disease. *J. Am. Soc. Nephrol.* 16: 2985-2996 IF: 8,987
- [33] Schena F.P., Cerullo G., Torres D.D., Scolari F., Foramitti M., Amoroso A., Pirulli D., Floege J., **Mertens P.R.**, Zerres K., Alexopoulos E., Kirmizis D., Zelante L., Bisceglia L. (2006) Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. *Eur. J. Hum. Genet.* 14: 488-496 IF: 4,319
- [34] Wu J., Yokom D., Jiang H., Cheang M.C., Yorida E., Turbin D., Berguin I.M., **Mertens P.R.**, Iftner T., Gilks C.B., Dunn S.E. (2006) Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. *Cancer Res.* 66: 4872-4879 IF: 8,650

- [35] Wiercinska E., Wickert L., Denecke B., Said H.M., Hamzavi J., Gressner A.M., Thorikay M., Ten Dijke P., **Mertens P.R.**, Breitkopf K., Dooley S. (2006) Id1 is a critical mediator in TGF- β -induced transdifferentiation of rat hepatic cells. *Hepatology* 43: 1032-1041 IF: 12,003
- [36] Dooley S., Said H.R., Gressner A.M., Floege J., En-Nia A., **Mertens P.R.** (2006) YB-1 is the crucial mediator of anti-fibrotic IFN- γ effects. *J. Biol. Chem.* 281: 1784-1795 IF: 4,651
- [37] Lynen-Jansen P., Rosch R., Rezvani M., **Mertens P.R.**, Junge K., Jansen M., Klinge U. (2006) Hernia fibroblasts lack beta-estradiol induced alterations of collagen gene expression. *BMC Cell Biol.* 7: 36 doi: 10.1186/1471-2121-7-36 IF: 2,808
- [38] Klinge U., Rosch R., Junge K., Krones C.J., Stumpf M., Lynen-Jansen P., **Mertens P.R.**, Schumpelick V. (2006) Different matrix micro-environments in colon cancer and diverticular disease. *Int. J. Colorectal Dis.* 22: 515-520 IF: 2,238
- [39] Seyhan H., Hamzavi J., Wiercinska E., Gressner A.M., **Mertens P.R.**, Kopp J., Horsch R.E., Breitkopf K., Dooley S. (2006) Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling. *J. Cell. Mol. Med.* 10: 922-932 IF: 4,735
- [40] Weng H., **Mertens P.R.**, Gressner A.M., Dooley S. (2006) IFN- γ abrogates profibrogenic TGF- β signaling in liver by targeting expression of inhibitory and receptor Smads *J. Hepatology* 46: 295-303 IF: 9,858
- [41] Bisceglia L., Cerullo G., Torres D.D., Di Perna M., Scolari F., Foramitti M., Amoroso A, Bertok S, Floege J, **Mertens P.R.**, Zerres K., Alexopoulos E., Kirmizis D., Ermelinda M., Zelante L., Schena F.P. (2006) Genetic heterogeneity in italian IgA nephropathy families: suggestive linkage of two novel IgAN loci. *Am. J. Hum. Genetics* 79: 1130-1134 IF:11,202
- [42] Stefanidou V., Liakopoulos V., Eleftheriadis T., Anifandis G., **Mertens P.R.**, Kanelaki E., Stefanidis I. (2007) Expression of transforming growth factor- β receptor II mRNA in cyclosporine-induced gingival overgrowth. *Transplant. Proc.* 38: 2905-2908 IF: 0,952
- [43] Bicanski B., Wenderdel M., Schlebusch P., **Mertens P.R.**, Senderek J., Panzer U., Steinmetz O., Stahl R.A.K., Schena F.P., Zerres K., Floege J. (2007) PDGF-B gene single-nucleotide polymorphism and susceptibility to and progression of IgA nephropathy. *Clin. Nephrol.* 67: 65-72 IF: 1,288
- [44] Lynen-Jansen P., Keuer M., Rosch R., Krott E., Jansen M., Alfonso-Jaume A., Dooley S., Klinge U., Lovett D.H., **Mertens P.R.** (2007) Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts. *FASEB J.* 21: 1047-1057 IF: 5,704
- [45] Junge K., Klinge U., Rosch R., Lynen P., Binnebosel M., Conze J., **Mertens P.R.**, Schwab R., Schumpelick V. (2007) Improved collagen type I/III ratio at the interface of gentamicin-supplemented polyvinylidene fluoride mesh materials. *Langenbecks Arch. Surg.* 392: 465-471 IF: 1,891

- [46] To K., Zhao Y., Jiang H., Hu K., Wang M., Wu J., Lee C., Yokom D.W., Stratford A.L., Klinge U., **Mertens P.R.**, Chen C.S., Bally M., Yapp D. and Dunn S.E. (2007) The phosphoinositide-dependent kinase-1 inhibitor, OSU-03012, prevents Y-box binding protein-1 (YB-1) from inducing epidermal growth factor receptor (EGFR). *Mol. Pharmacol.* 72: 641-52 IF: 4,411
- [47] Lynen-Jansen P., Rosch R., Jansen M., Binnebösel M., Junge K., Alfonso-Jaume A., Klinge U., Lovett D.H., **Mertens P.R.** (2007) Regulation of MMP-2 gene transcription in dermal wounds. *J. Invest. Dermatol.* 127: 1762-1767 IF: 6,193
- [48] Stratford A.L., Habibi G., Astanehe A., Jiang H., Hu K., Park E., Shadeo A., Buys T.P., Lam W., Pugh T., Marra M., Nielsen T.O., Klinge U., **Mertens P.R.**, Aparicio S., Dunn S.E. (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. *Breast Cancer Res.* 9: R61 IF: 5,872
- [49] Krohn R., Raffetseder U., Bot I., Zerneck A., Shagdarsuren E., Liehn E.A., van Santbrink P.J., Nelson P.J., Biessen E.A., **Mertens P.R.** *, Weber C.* (2007) YB-1 controls CCL5 expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. *Circulation* 116: 1812-1820 (*equal contribution) IF: 15,202
- [50] Kourti P., Zarogliannis S., Liakopoulos V., Hatzoglou C., Giannopoulou M., Chronopoulou I., **Mertens P.R.**, Potamianos S., Gourgoulialis K., Molyvdas P.A., Stefanidis I. (2007) Effect of endothelin-1 on the transmesothelial resistance of isolated sheep peritoneum. *Adv. Perit. Dial.* 23: 38-42 IF: -
- [51] Fraser D.J., Phillips A.O., Zhang X., van Roeyen C.R.C., Muhlenberg P., **Mertens P.R.** (2008) Y-box protein-1 controls transforming growth factor-beta1 translation in proximal tubular cells. *Kidney Int.* 73: 724-732 IF: 7,916
- [52] Molnar G.A., Lindschau C., Dubrovskaja G., **Mertens P.R.**, Kirsch T., Quinkler M., Gollasch M., Wresche S., Luft F.C., Muller D.N., Fiebeler A. (2008) Glucocorticoid-related signaling effects in vascular smooth muscle cells. *Hypertension* 51: 1372-1378 IF: 6,873
- [53] Sakkas G.K., Hadjigeorgiou G.M., Karatzaferi C., Maridaki M.D., Giannaki C.D., **Mertens P.R.**, Rountas C., Vlychou M., Liakopoulos V., Stefanidis I. (2008) Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis: a pilot study. *ASAIO J.* 54: 185-190 IF: 1,491
- [54] Schwab M., Lupescu A., Mota M., Mota E., Frey A., Simon P., **Mertens P.R.**, Floege J., Luft F., Asante-Poku S., Schaeffeler E., Lang F. (2008) Association of the SGK1 gene with type 2 diabetes. *Cell. Physiol. Biochem.* 21: 151-160 IF: 3,415
- [55] Liakopoulos V., Petinaki E., Efthimiadi G., Klapsa D., Giannopoulou M., Dovas S., Eleftheriadis T., **Mertens P.R.**, Stefanidis I. (2008) Clonal relatedness of methicillin-resistant coagulase-negative staphylococci in the hemodialysis unit of a single university centre in Greece. *Nephrology Dialysis Transplantation* 23: 2599-603 IF: 3,371

- [56] Hamzavi J., Ehnert S., Godoy P., Ciuculan L., Weng H., **Mertens P.R.**, Heuchelö R., Dooley S. (2008) Disruption of the Smad7 gene enhances CCl(4)-dependent liver damage and fibrogenesis in mice.
J. Cell. Mol. Med. 12: 2130-44 IF: 4,753
- [57] Dooley S., Hamzavi J., Weng H., Ciuculan L., Godoy P., Ilkavets I., Ehnert S., Ueberham E., Gebhardt R., Kanzler S., Geier A., Breitkopf K., **Mertens P.R.** (2008) Hepatocyte-specific Smad7 expression attenuates TGF- β -mediated fibrogenesis and protects against liver damage.
Gastroenterology 135: 642-59 IF: 12,821
- [58] Raffetseder U., Rauen T., Djurdjaj S., Kretzler M., En-Nia A., Tacke F., Zimmermann H.W., Nelson P.J., Frye B.C., Floege J., Stefanidis I., Weber C., **Mertens P.R.** (2009) Differential regulation of the chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1.
Kidney Int. 75: 185-96 IF: 7,916
- [59] Malycha F., Eggermann T., Hristov M., Schena F.P., **Mertens P.R.**, Zerres K., Floege J., Eitner F. (2009) No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients.
Nephrology Dialysis Transplantation 24: 321-4 IF: 3,371
- [60] Finkbeiner M.R., Astanehe A., To K., Fotovati A., Davies A.H., Zhao Y., Jiang H., Stratford A.L., Shadeo A., Boccaccio C., Comoglio P., **Mertens P.R.**, Eirew P., Rapouf A., Eaves C.F., Dunn S.E. (2009) Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
Oncogene 28: 1421-31 IF: 7,357
- [61] Boor P., Eitner F., Cohen C.D., Lindenmeyer M.T.; for the ERCB-consortium, **Mertens P.R.**, Ostendorf T., Floege J. (2009) Patients with IgA nephropathy exhibit high systemic PDGF-DD levels.
Nephrology Dialysis Transplantation 24: 2755-62 IF: 3,371
- [62] Weng H.L., Liu Y., Chen J.L., Huang T., Xu L.J., Godoy P., Hu J.H., Zhou C., Stickel F., Marx A., Bohle R.M., Zimmer V., Lammert F., Mueller S., Gigou M., Samuel D., **Mertens P.R.**, Singer M.V., Seitz H.K., Dooley S. (2009) The etiology of liver damage imparts cytokine transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis.
Hepatology 50: 230 -43 IF: 12,003
- [63] Frye B.C., Halfter S., Djurdjaj S., Muehlenberg P., Weber S., Halfter S., Raffetseder U., En-Nia A., Knott H., Baron J.M., Dooley S., Bernhagen J., **Mertens P.R.** (2009) Y-box protein-1 is actively secreted via a non-classical pathway and acts as an extracellular mitogen.
EMBO Reports 10: 783-9 IF: 7,189
- [64] Lutz H.H., Ackermann T., Krombach G.A., Gröne H.-J., Rauen T., Floege J., **Mertens P.R.** (2009) Henoch-Schönlein Purpura Complicated by Cardiac Involvement: Case Report and Review of the Literature.
Am. J. Kidney Dis. 54: e9-15 IF: 5,294
- [65] Rauen T., Michaelis A., Floege J., **Mertens P.R.** (2009) Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24.
Clinical Nephrol. 71: 637-42 IF: 1,288

- [66] Dooley S, Weng H, **Mertens PR**. (2009) Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma. *Dig Dis*. 27:93-101 IF: 2,725
- [67] Rauen T, Raffetseder U, Frye BC, Djudjaj S, Mühlenberg PJ, Eitner F, Lendahl U, Bernhagen J, Dooley S, **Mertens PR**. (2009) YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. *J Biol Chem*. 284:26928-40 IF: 4,651
- [68] Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, **Mertens PR**. (2009) Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. *BMC Cancer*. 9: 410 IF: 3,333
- [69] Wachowiak R, Thieltges S, Rawnaq T, Kaifi JT, Fiegel H, Metzger R, Quaas A, **Mertens PR**, Till H, Izbicki JR. (2010) Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. *Anticancer Res*. 30: 1239-42 IF: 1,713
- [70] Lovett DH, Cheng S, Cape L, Pollock AS, **Mertens PR**. (2010) YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. *Biochem Biophys Res Commun*. 398: 482-8 IF: 2,406
- [71] Raffetseder U, Rauen T, Boor P, Ostendorf T, Hanssen L, Floege J, En-Nia A, Djudjaj S, Frye BC, **Mertens PR**. (2011) Extracellular YB-1 blockade in experimental nephritis upregulates Notch-3 receptor expression and signaling. *Nephron Exp Nephrol*. 118: e100-8 IF: 2,013
- [72] Wu YJ, Cai WM, Li Q, Liu Y, Shen H, **Mertens PR**, Dooley S, Weng HL. (2011) Long-term antifibrotic action of interferon- γ treatment in patients with chronic hepatitis B virus infection. *Hepatobiliary Pancreat Dis Int*. 10: 151-7 IF: 1,259
- [73] Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA, **Mertens PR**. (2011) The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. *J Am Coll Cardiol*. 57: 1752-61 IF: 14,086
- [74] Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, Trautwein C, **Mertens PR**. (2011) Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. *BMC Cancer*. 11:185 IF: 3,333
- [75] Hanssen L, Frye BC, Ostendorf T, Alidousty C, Djudjaj S, Boor P, Rauen T, Floege J, **Mertens PR**, Raffetseder U. (2011) Y-box binding protein-1 mediates profibrotic effects of calcineurin inhibitors in the kidney. *J Immunol*. 187: 298-308 IF: 5,520
- [76] Haase M, Bellomo R, Story D, Letis A, Klemz K, Matalanis G, Seevanayagam S, Dragun D, Seeliger E, **Mertens PR**, Haase-Fielitz A. (2012) Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. *Nephrol Dial Transplant*. 27: 153-60 IF: 3,371

- [77] Liu Y, Meyer C, Müller A, Herweck F, Li Q, Müllenbach R, **Mertens PR**, Dooley S, Weng HL. (2012) IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF- β -independent Smad signaling. *J Immunol.* 187: 2814-23 IF: 5,520
- [78] Haase-Fielitz A, **Mertens PR**, Plass M, Kuppe H, Hetzer R, Westerman M, Ostland V, Prowle JR, Bellomo R, Haase M. (2011) Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study. *Crit Care.* 15:R186. IF: 4,718
- [79] Raffetseder U, Liehn EA, Weber C, **Mertens PR**. (2012) Role of cold shock Y-box protein-1 in inflammation, atherosclerosis and organ transplant rejection. *Eur J Cell Biol.* 91: 567-75 IF: 3,213
- [80] Brandt S, Raffetseder U, Djudjaj S, Schreiter A, Kadereit B, Michele M, Pabst M, Zhu C, **Mertens PR**. (2012) Cold shock Y-box protein-1 participates in signaling circuits with auto-regulatory activities. *Eur J Cell Biol.* 91: 464-71 IF: 3,213
- [81] **Mertens PR**, Martin IV, Frye BC, Rauen T, Strauch S, Pabst M, Geier A. (2012) Rat Mrp2 gene expression is regulated by an interleukin-1 β -stimulated biphasic response with enhanced transcription and subcellular shuttling of YB-1. *Eur J Cell Biol.* 91: 533-41 IF: 3,213
- [82] Djudjaj S, Chatziantoniou C, Raffetseder U, Guerrot D, Dussaule JC, Boor P, Kerroch M, Hanssen L, Brandt S, Dittrich A, Ostendorf T, Floege J, Zhu C, Lindenmeyer M, Cohen CD, **Mertens PR**. (2012) Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. *J Pathol.* 228: 286-99 IF: 7,585
- [83] Stielke S, Keilhoff G, Kirches E, **Mertens PR**, Neumann KH, Tsokos GC, Mawrin C. (2012) Adhesion molecule expression precedes brain damages of lupus-prone mice and correlates with kidney pathology. *J Neuroimmunol.* 252: 24-32 IF: 3,033
- [84] Haase-Fielitz A, Plaß M, Kuppe H, Hetzer R, Ostland V, Westphal S, Hoffmann J, Prowle J, **Mertens PR**, Westerman M, Bellomo R, Haase M. (2013) Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: a pilot study. *J Thorac Cardiovasc Surg.* 145: 1380-6 IF: 3,526
- [85] Weng HL, Feng DC, Radaeva S, Kong XN, Wang L, Liu Y, Li Q, Shen H, Gao YP, Müllenbach R, Munker S, Huang T, Chen JL, Zimmer V, Lammert F, **Mertens PR**, Cai WM, Dooley S, Gao B. (2013) IFN- γ inhibits liver progenitor cell proliferation in HBV-infected patients and in 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-fed mice. *J Hepatol.* (in press) IF: 9,858
- [86] Weng HL, Feng DC, Radaeva S, Kong XN, Wang L, Liu Y, Li Q, Shen H, Gao YP, Müllenbach R, Munker S, Huang T, Chen JL, Zimmer V, Lammert F, **Mertens PR**, Cai WM, Dooley S, Gao B. (2013) IFN- γ inhibits liver progenitor cell proliferation in HBV-infected patients and in 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-fed mice. *J Hepatol.* 59:738-45 IF: 9,858
- [87] Hanssen L, Alidousty C, Djudjaj S, Frye BC, Rauen T, Boor P, **Mertens PR**, van Roeyen CR, Tacke F, Heymann F, Tittel AP, Koch A, Floege J, Ostendorf T,

- Raffetseder U. (2013) YB-1 is an early and central mediator of bacterial and sterile inflammation In vivo.
J Immunol. 191: 2604-13 IF: 5,520
- [88] Heller A, Westphal SE, Bartsch P, Haase M, **Mertens PR.** (2013) Chronic kidney disease is associated with high abdominal incisional hernia rates and wound healing disturbances.
Int Urol Nephrol. (in press) IF: 1,325
- [89] Van Roeyen CR, Scurt FG, Brandt S, Kuhl VA, Martinkus S, Djudjaj S, Raffetseder U, Royer HD, Stefanidis I, Dunn SE, Dooley S, Weng H, Fischer T, Lindquist JA, **Mertens PR.** (2013) Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities.
Cell Commun Signal 11:63 IF: 5,50
- [90] Tacke F, Galm O, Kanig N, Yagmur E, Brandt S, Lindquist JA, Eberhardt CS, Raffetseder U, **Mertens PR.** (2014) High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin.
BMC Cancer 14:33 IF: 3,333
- [91] Heller A, Westphal SE, Bartsch P, Haase M, **Mertens PR.** (2014) Chronic kidney disease is associated with high abdominal incisional hernia rates and wound healing disturbances.
Int Urol Nephrol. (in press) IF: 1,325
- [92] Albert C, von Schultendorff M, Şalaru D, Halloul Z, Dragun D, Heidecke H, **Mertens PR.** (2014) In arterial occlusive disease autoantibodies against ETAR and AT(1)R correlate with each other but are not associated with classical cardiovascular risk factors.
Vasa 43:113-23 IF: 1,009
- [93] Bouchlariotou S, Liakopoulos V, Giannopoulou M, Arampatzis S, Eleftheriadis T, **Mertens PR,** Zintzaras E, Messinis IE, Stefanidis I. (2014) Melatonin secretion is impaired in women with preeclampsia and an abnormal circadian blood pressure rhythm.
Ren Fail. 16:1-7 IF: 1,050
- [94] Stefanidis I, Kreuer K, Dardiotis E, Arampatzis S, Eleftheriadis T, Hadjigeorgiou GM, Zintzaras E, **Mertens PR.** (2014) Association Between the Interleukin-1 β Gene (IL1B) C-511T Polymorphism and the Risk of Diabetic Nephropathy in Type 2 Diabetes: A Candidate-Gene Association Study.
DNA Cell Biol. (in press) IF: 2,344
- [95a] Bernstein HG, Lindquist JA, Keilhoff G, Dobrowolny H, Brandt S, Steiner J, Bogerts B, **Mertens PR.** (2014) Differential distribution of Y-box-binding protein 1 and cold shock domain protein A in developing and adult human brain.
Brain Struct Funct. (in press) IF: 7,837
- [95b] Bernstein HG, Lindquist JA, Keilhoff G, Dobrowolny H, Brandt S, Steiner J, Bogerts B, **Mertens PR.** (2014) Erratum to: Differential distribution of Y-box-binding protein 1 and cold shock domain protein A in developing and adult human brain.
Brain Struct Funct. (in press)

- [96] Alidousty C, Rauen T, Hanssen L, Wang Q, Alampour-Rajabi S, **Mertens PR**, Bernhagen J, Floege J, Ostendorf T, Raffetseder U. (2014) Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation. *J Biol Chem.* 289(31):21401-12 IF: 4,651
- [97] Salaru DL, Albert C, Königsmark U, Brandt S, Halloul Z, Heller A, Heidecke H, Dragun D, **Mertens PR** (2014) Serum levels of midkine, a heparin-binding growth factor, inversely correlate with angiotensin and endothelin receptor autoantibody titers in patients with macroangiopathy. *Int Angiol* 33: 371 -378 IF: 1,04
- [98] Albert C, Kube J, Haase-Fielitz A, Dittrich A, Schanze D, Zenker M, Kuppe H, Hetzer R, Bellomo R, **Mertens PR**, Haase M. (2014) Pilot study of association of catechol-O-methyl transferase rs4680 genotypes with acute kidney injury and tubular stress after open heart surgery. *Biomark Med.* 8:1227-38. IF: 2,858
- [99] Feng T, Dzieran J, Gu X, Marhenke S, Vogel A, Machida K, Weiss TS, Rümmele P, Kollmar O, Hoffmann P, Graesser F, Allgayer H, Fabian J, Weng HL, Teufel A, Maass T, Meyer C, Lehmann U, Zhu C, **Mertens PR**, Gao CF, Dooley S, Meindl-Beinker NM. (2015) Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. *Clin Sci (Lond)* (in press) IF: 5,62
- [100] Li H, Xia Q, Zeng B, Li ST, Liu H, Li Q, Li J, Yang SY, Dong XJ, Gao T, Munker S, Liu Y, Liebe R, Xue F, Li QG, Chen XS, Liu Q, Zeng H, Wang JY, Xie Q, Meng QH, Wang JF, **Mertens PR**, Lammert F, Singer MV, Dooley S, Ebert MP, Qiu K, Wang TL, Weng HL. (2015) Submassive hepatic necrosis distinguishes HBV-associated acute-on chronic liver failure from cirrhotic patients with acute decompensation. *J Hepatol* (in press) IF: 10,4

FALLBERICHTE, BRIEFE UND KONGRESSARTIKEL

- [1] **Mertens P.R.**, Schönfelder T., Handt S., Marschall H.-U., Kierdorf H., Busch N., Heintz B., and Sieberth, H.-G. (1998) Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmapheresis. *Blood Purif.* 16: 341-348 IF: 2,062
- [2] Stefanidis I., Heintz B., Frank D., **Mertens P.R.**, and Kierdorf H.P. (1999) Influence of hematocrit on hemostasis in continuous venovenous hemofiltration during acute renal failure. *Kidney Int. Suppl.* 72: S51-55 IF: 7,916
- [3] **Mertens P.R.**, Kopp R., Kierdorf H., Busch N., Matern S., Sieberth H.G. (2000) 66-year-old patient with myxedema and polyserositis. *Internist* 41: 161-164 IF: 0,329
- [4] Brandenburg V.M., **Mertens P.R.**, Block F., Riehl J. (2001) Recurrent hypocalcemic tetany, generalized seizures and increased bronchopulmonary infections in an 18-year-old patient. *Internist* 42: 1035-1038 IF: 0,329
- [5] Siewert E., Silvestri A., Riehl J., **Mertens P.R.** (2001) 32-year old patient presenting with autoimmune polyglandular syndrome. *Eur. J. Med. Res.* 29: 21-26 IF: 1,098

- [6] Brandenburg V.M., Krueger S., Haage P., **Mertens P.R.**, Riehl J. (2002) Heterotaxy syndrome with severe pulmonary hypertension in an adult. *South. Med. J.* 95: 536-538 IF: 0,915
- [7] Stefanidis I., Wurth P., **Mertens P.R.**, Ikononov V., Philippidis G., Golphinopoulos S., Makropoulos V., Liakopoulos V., Mann H., Heintz B. (2005) Plasma endothelin-1 in hemodialysis treatment - the influence of hypertension. *J. Cardiovasc. Pharmacol.* 44: S43-48 IF: 2,383
- [8] Stefanidis I., Liakopoulos V., Kapsoritakis A.N., Ioannidis I., Eleftheradis T., **Mertens P.R.**, Winograd R., Vamvaka E., Psychos A.K., Potamianos S.P. (2006) Gastric antral vascular ectasia (watermelon stomach) in patients with ESRD. *Am. J. Kidney Dis.* 47: e77-82 IF: 5,294
- [9] Liakopoulos V., **Mertens P.R.**, Eleftheriadis T., Koukoulis G., Stefanidis I. (2006) Is there a link between inflammation, plasma resistin levels, protein malnutrition in hemodialysis patients? *Kidney Int.* 70: 1371-1372 IF: 7,916
- [10] Klinge U., Ackermann D., Lynen-Jansen P., **Mertens P.R.** (2008) The risk to develop a recurrence of a gastric cancer – is it independent of time? *Langenbecks Arch. Surg.* 393: 149-155 IF: 1,891
- [11] **Mertens P.R.**, Raffetseder U., Rauen T. (2008) Notch receptors: a new target in glomerular diseases. *Nephrology Dialysis Transplantation* 23: 2743-5 IF: 3,371
- [12] Steinbach J, Bartsch P, Langer D, Bosselmann HP, Neumann KH, **Mertens PR.** (2010) [Necrotizing granulomatosis with pulmonary, intestinal and renal involvement]. *Med Klin (Munich).* 105: 831-6 IF: -
- [13] Motzkau M, Meyer P, **Mertens PR**, Klose S. (2012) Monogenic diabetes in a family with 2 unknown HNF-4A gene mutations. *Exp Clin Endocrinol Diabetes.* 120: 89-90 IF: 1,555
- [14] Albert C, Haase M, Bellomo R, **Mertens PR.** (2012) High cut-off and high-flux membrane haemodialysis in a patient with rhabdomyolysis-associated acute kidney injury. *Crit Care Resusc.* 14:159-62 IF: 1,507

REVIEW ARTIKEL

- [1] **Mertens P.R.** and Floege J. (2000) Treatment of IgA nephropathies: a critical viewpoint. *Dtsch. Med. Wochenschr.*, 125:1010 IF: -
- [2] Floege J. and **Mertens P.R.** (2000) Therapy of patients with IgA-nephropathy: a critical appraisal. *Kidney Blood Press Res.*, 23:207-209 IF: 1,596
- [3] **Mertens P.R.** and Floege J. (2003) IgA-Nephropathie: Die häufigste Glomerulonephritis-Form. *Dtsch. Med. Wochenschr.*, 128:1242-1246 IF: -
- [4] Klinge U., Junge K., **Mertens P.R.** (2004) Herniosis: A biological approach. *Hernia* 8: 300-1 IF: 1,693

- [5] **Mertens P.R.** (2005) Update Glomerulonephritis.
Spektrum der Nephrologie (05/2005) IF: -
- [6] **Mertens P.R.** (2007) Genetik der IgA-Nephropathie.
Nephro News, Jahrgang 9, Ausgabe 3/07, 32-33 IF: -
- [7] **Mertens PR**, Müller R. (2010) Vitamin D and cardiovascular risk.
Int Urol Nephrol. 42:165-71 IF: 1,325
- [8] Rauen T, **Mertens PR.** (2010) Unravelling the pathogenesis of lupus nephritis: novel genetic study confirms decisive contribution of circulating colony-stimulating factor-1 (CSF-1).
Int Urol Nephrol. 42: 519-21 IF: 1,325
- [9] Zhu C, **Mertens PR.** (2010) Epithelial-mesenchymal transition to be or not to be? Is the answer yes and no at the same time?
Int Urol Nephrol. 42:843-6 IF: 1,325
- [10] Haase M, **Mertens PR.** (2010) Urinary biomarkers--silver bullets to faster drug development and nephron protection.
Nephrol Dial Transplant. 25: 3167-9 IF: 3,371
- [11] Shpacovitch V, **Mertens PR.** (2010) High mobility group box protein-1 crossing cell borders may incite an inflammatory "tornado" in renal disease.
Int Urol Nephrol. 42: 847-50 IF: 1,325
- [12] Zenker M, **Mertens PR.** (2010) Arrest of the true culprit and acquittal of the innocent? Genetic revelations charge APOL1 variants with kidney disease susceptibility.
Int Urol Nephrol. 42: 1131-4 IF: 1,325
- [13] Haase M, Haase-Fielitz A, Bellomo R, **Mertens PR.** (2010) Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease.
Curr Opin Hematol. PMID: 21102325 IF: 4,111
- [14] Pabst M, **Mertens PR.** (2011) What is important to target fibrosis: location, location, location! of cold-shock proteins.
Int Urol Nephrol. 43: 589-91 IF: 1,325
- [15] Haase M, **Mertens PR**, Haase-Fielitz A. (2011) Renal stress in vivo in real-time--visualised by the NGAL reporter mouse.
Nephrol Dial Transplant. 26: 2109-11 IF: 3,371
- [16] Albert C, **Mertens PR**, Bartsch P. (2011) Urea and atherosclerosis--evidence for a direct link involving apolipoprotein B protein modifications.
Int Urol Nephrol. 43: 933-6 IF: 1,325
- [17] Haase M, Haase-Fielitz A, **Mertens PR.** (2012) A novel link: in children, cow milk processing may be causative of idiopathic membranous nephropathy.
Int Urol Nephrol. 44: 635-8 IF: 1,325
- [18] Brandt S, **Mertens PR.** (2012) Epidermal growth factor receptor mediates injury in rapidly progressive glomerular disease.
Int Urol Nephrol. 44: 971-5 IF: 1,325
- [19] Zhu C, **Mertens PR.** (2012) IgA nephropathy and oxidative stress: news on clinically evaluated biomarkers hits the stage.

- Int Urol Nephrol.* 44: 1277-80 IF: 1,325
- [20] Zhu C, **Mertens PR.** (2013) Podocytes proliferate: novel mechanism identified in collapsing glomerulopathies. *Int Urol Nephrol.* 45: 275-9 IF: 1,325
- [21] Salaru DL, **Mertens PR.** (2013) Lessons from the heart and ischemic limbs: midkine as anti-inflammatory mediator for kidney diseases? *Int Urol Nephrol.* 45: 893-7 IF: 1,325
- [22] Salaru DL, **Mertens PR,** Bartsch P. (2013) Loss of heparin-binding protein prevents necrotizing glomerulonephritis: first clues hint at plasminogen activator inhibitor-1. *Int Urol Nephrol.* 45: 1483-7 IF: 1,325
- [23] Lindquist J, **Mertens PR** (2013) Myofibroblasts, the bogeymen of renal fibrosis. *Nephrol Dial Transplant.* (in press) IF: 3,371

BUCHKAPITEL

- [1] **Mertens P.R.** und Floege J., Kapitel VI-1.1. Glomerulonephritis – Pathogenese und klinische Verläufe. In Franz/Risler: Klinische Nephrologie (09/01).
- [2] **Mertens P.R.,** Schulze M. und Floege J., Kapitel VI-1.4. Membranöse Glomerulonephritis. In Franz/Risler: Klinische Nephrologie (09/01).
- [3] **Mertens P.R.** und Floege J., Kapitel VI-1.5. Membranoproliferative Glomerulonephritis. In Franz/Risler: Klinische Nephrologie (09/01).
- [4] Floege J. und **Mertens P.R.,** Kapitel VI-1.5. Membranoproliferative Glomerulonephritis. In Franz/Risler: Klinische Nephrologie (09/01).
- [5] Jansen P.L., Knops M., Rosch R. und **Mertens P.R.** (2003) Collagen - The crucial cause of hernia disease. In Mesh: Benefits and risks (pages 76-80). Eds. V. Schumpelick, L. Nyhus, Springer Verlag.
- [6] **Mertens P.R.,** Lynen-Jansen P., Klinge U. (2007) Identification of the patients at risk (for recurrent hernia disease) In Recurrent Hernia: Prevention and Treatment (pages 397-400). Eds. V. Schumpelick, R.J. Fitzgibbons, Springer Verlag.
- [7] Haase M. **Mertens P.R.** (2011) Diagnostische Methoden in der Nephrologie. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.
- [8] Floege J., **Mertens P.R.** (2012) Glomeruläre Nierenerkrankungen. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.
- [9] Wolf G., **Mertens P.R.** (2012) Diabetische Nephropathie. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.
- [10] Kettritz R., **Mertens P.R.,** Haubitz M. (2012) Renale Vaskulopathien einschließlich Vaskulitiden. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.
- [11] Haase M., **Mertens P.R.,** Grabensee B., Schindler R. (2012) Akutes Nierenversagen. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.
- [12] Heemann U., Girndt M., **Mertens P.R.** (2011) Nierentransplantation. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.
- [13] Böger CA, **Mertens P.R.** (2013) Genetic risk factors for diabetic nephropathy. In: Diabetes and Kidney Disease, Edited by Gunter Wolf, Wiley Blackwell Verlag.

- [14] Galle J., **Mertens P.R.** (2014) Chronische Nierenerkrankungen. In: Rationelle Diagnostik und Therapie in der Inneren Medizin, Elsevier Verlag.

Patente

- Verfahren zur Bestimmung entzündlicher Vorgänge anhand des sekretierten Proteins YB-1 und Fragmente dieses Proteins. (Deutsches Patent: 10 2004 060 385.5, PCT ist angemeldet)
- Schutzeinrichtung für den diabetischen Fuss und Verfahren zum Schutz des diabetischen Fußes vor fehlender Durchblutung (Deutsches Patent ist angemeldet, PCT WO 2012/084814 A1)

Doktoranden mit abgeschlossenen Promotionsarbeiten

| Name | Thema der Arbeit | Abschluß | Note |
|--------------------------------|---|----------|---|
| Dr. rer. nat. Abdelaziz En-Nia | Transkriptionelle Regulation der Kollagensynthese und des Matrixabbaus in Mesangialzellen | 2002 | <i>magna cum laude</i> |
| Dr. med. Julia Reisdorf | Der Transkriptionsfaktor Ets-1 reguliert die Gelatinase A-Genexpression in Mesangialzellen | 2003 | <i>summa cum laude</i> Friedrich Wilhelm-Preis für herausragende Promotion der RWTH-Aachen |
| Dr. med. Björn Frye | Identifizierung und funktionelle Charakterisierung des Spleißfaktors SRp30c als Interaktionspartner des Y-box Proteins-1 (YB-1) | 2004 | <i>summa cum laude</i> 1. Platz: Fakultätspreis für herausragende Promotion |
| Dr. med. Emek Yilmaz | Regulation des DNA Polymerase α -Gens durch den Transkriptionsfaktor YB-1 | 2005 | <i>summa cum laude</i> Friedrich Wilhelm-Preis für herausragende Promotion der RWTH-Aachen |
| Dr. med. Sandra Martinkus | Mapping funktionaler Domänen für den nukleären Export und Import von YB-1 | 2008 | <i>summa cum laude</i> |
| Dr. med. Renate Krings | Etablierung und Charakterisierung von monoklonalen Antikörpern gegen YB-1 | 2008 | <i>magna cum laude</i> |
| Dr. med. Hanna Knott | Aufklärung von YB-1 Proteinmodifikationen nach Stimulation mit PDGF-B | 2008 | <i>magna cum laude</i> |
| Dr. med. Thomas Rauen | Charakterisierung von Notch-3 als YB-1 Rezeptor | 2008 | <i>summa cum laude</i> |
| Dr. med. Vanessa Kuhl | Identifizierung und Kartierung von nukleären Import- und Exportsignalmotiven innerhalb des Y-box bindenden Proteins-1 (YB-1) | 2008 | <i>magna cum laude</i> |
| Dr. med. Sarah Maria Halfter | Nachweis der Sekretion eines Kälteschockproteins und Aufklärung zugrundeliegender Exportmechanismen | 2010 | <i>summa cum laude</i> |
| Dr. med. Sabrina Thielges | Einfluss des Transkriptionsfaktors Y-box Protein-1 auf die Zellproliferation und den aktivierten Mesangialzell-Phänotyp | 2010 | <i>magna cum laude</i> |
| Dr. med. Saskia Westphal | Erstellung eines Risikoprofils für Wundheilungsstörungen: Eine prospektive Studie | 2010 | <i>magna cum laude</i> |
| Dr. med. Niklas Kanig | Der Nachweis von Y-box Protein-1 (YB-1)-Proteinfragmenten im humanen Serum als Marker für maligne Erkrankungen | 2010 | <i>magna cum laude</i> |
| Dr. rer. Medic Cheng Zhu | Expression and regulation of cold shock proteins in inflammatory kidney and liver diseases | 2012 | <i>magna cum laude</i> |
| Dr. rer. nat. Sonja Djudaj | Untersuchungen zur Rolle von Notch-3 Rezeptoren in experimentellen Schädigungsmodellen der Niere | 2012 | <i>magna cum laude</i> |
| Dr. med. Christiane Eberhard | Nachweis und Charakterisierung von Autoantikörpern gegen das Protein YB-1 bei onkologischen Patienten | 2013 | <i>magna cum laude</i> |

Betreuung MD/PhD-Programm

| Name | Thema der Arbeit | Förderung | Zeitraum |
|---------------------|---|--------------------------------|-------------------|
| Dr. med. Björn Frye | Einfluß des Y-box Proteins 1 auf die Notch-Signaltransduktion und Zelldifferenzierung | Rotationsstelle START-Programm | Abschluss 12/2007 |

Betreuung Habilitation

| Name | Thema der Arbeit | Förderung | Zeitraum |
|----------------------|---|-------------------------|--|
| Dr. med. Petra Lynen | Molekulare Untersuchungen zur Herniogenese und Reparatur mit Biomaterialien | Lise-Meitner Stipendium | 01/2005-12/2007 Habilitation abgeschlossen 06/2008 |
| Dr. Ute Raffetseder | Die Rolle des Kälteschockproteins YB-1 im entzündlichen Geschehen | | Habilitation abgeschlossen 01/2013 |